Page 20 - OR-1-2

of lysosomal proteolysis in astrocytes facilitates midbrain and inflammatory defects in GBA1-mutant astrocytes
organoid proteostasis failure in an early-onset Parkinson’s are normalized by LRRK2 inhibition. Mov Disord.
disease model. Nat Commun. 2024;15(1):447. 2020;35(5):760-773.
doi: 10.1038/s41467-024-44732-2 doi: 10.1002/mds.27994
49. Boussaad I, Obermaier CD, Hanss Z, et al. A patient-based 60. Li ZF, Cui L, Jin MM, et al. A matrigel-based 3D construct
model of RNA mis-splicing uncovers treatment targets in of SH-SY5Y cells models the α-synuclein pathologies of
Parkinson’s disease. Sci Transl Med. 2020;12(560):eaau3960. Parkinson’s disease. Dis Model Mech. 2022;15(3):dmm049125.
doi: 10.1126/scitranslmed.aau3960 doi: 10.1242/dmm.049125
50. Sidransky E, Samaddar T, Tayebi N. Mutations in GBA are 61. Chlebanowska P, Tejchman A, Sulkowski M, Skrzypek K,
associated with familial Parkinson disease susceptibility and Majka M. Use of 3D organoids as a model to study idiopathic
age at onset. Neurology. 2009;73(17):1424-1425, author reply form of Parkinson’s disease. Int J Mol Sci. 2020;21(3):694.
1425-1426.
doi: 10.3390/ijms21030694
doi: 10.1212/WNL.0b013e3181b28601
62. Elitt MS, Barbar L, Tesar PJ. Drug screening for human
51. Nichols WC, Pankratz N, Marek DK, et al. Mutations in GBA genetic diseases using iPSC models. Hum Mol Genet.
are associated with familial Parkinson disease susceptibility 2018;27(R2):R89-R98.
and age at onset. Neurology. 2009;72(4):310-316.
doi: 10.1093/hmg/ddy186
doi: 10.1212/01.wnl.0000327823.81237.d1
63. Cetin S, Knez D, Gobec S, Kos J, Pislar A. Cell models
52. Rosety I, Zagare A, Saraiva C, et al. Impaired neuron for Alzheimer’s and Parkinson’s disease: At the interface
differentiation in GBA-associated Parkinson’s disease is of biology and drug discovery. Biomed Pharmacother.
linked to cell cycle defects in organoids. NPJ Parkinsons Dis. 2022;149:112924.
2023;9(1):166.
doi: 10.1016/j.biopha.2022.112924
doi: 10.1038/s41531-023-00616-8
64. Zhang QS, Heng Y, Mou Z, Huang JY, Yuan YH,
53. Zagare A, Hemedan A, Almeida C, et al. Insulin resistance Chen NH. Reassessment of subacute MPTP-treated mice
is a modifying factor for Parkinson’s disease. Mov Disord. as animal model of Parkinson’s disease. Acta Pharmacol Sin.
2024;40(1):67-76. 2017;38(10):1317-1328.
doi: 10.1002/mds.30039 doi: 10.1038/aps.2017.49
54. Frattini E, Faustini G, Lopez G, et al. Lewy pathology 65. Cannon JR, Tapias V, Na HM, Honick AS, Drolet RE,
formation in patient-derived GBA1 Parkinson’s disease Greenamyre JT. A highly reproducible rotenone model of
midbrain organoids. Brain. 2025;148(4):1242-1257. Parkinson’s disease. Neurobiol Dis. 2009;34(2):279-290.
doi: 10.1093/brain/awae365 doi: 10.1016/j.nbd.2009.01.016
55. Baden P, Perez MJ, Raji H, et al. Glucocerebrosidase is 66. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ,
imported into mitochondria and preserves complex I integrity Lee VM. Neuronal alpha-synucleinopathy with severe
and energy metabolism. Nat Commun. 2023;14(1):1930. movement disorder in mice expressing A53T human alpha-
synuclein. Neuron. 2002;34(4):521-533.
doi: 10.1038/s41467-023-37454-4
doi: 10.1016/s0896-6273(02)00682-7
56. Jo J, Yang L, Tran HD, et al. Lewy body-like inclusions in
human midbrain organoids carrying glucocerebrosidase and 67. Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse
α-synuclein mutations. Ann Neurol. 2021;90(3):490-505. model of Parkinson’s disease. Nat Protoc. 2007;2(1):141-151.
doi: 10.1002/ana.26166 doi: 10.1038/nprot.2006.342
57. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease 68. Kim MS, Ra EA, Kweon SH, et al. Advanced human
glucocerebrosidase and α-synuclein form a bidirectional iPSC-based preclinical model for Parkinson’s disease with
pathogenic loop in synucleinopathies. Cell. 2011; optogenetic alpha-synuclein aggregation. Cell Stem Cell.
146(1):37-52. 2023;30(7):973-986.e11.
doi: 10.1016/j.cell.2011.06.001 doi: 10.1016/j.stem.2023.05.015
58. Ysselstein D, Nguyen M, Young TJ, et al. LRRK2 kinase 69. Zhu W, Tao M, Hong Y, et al. Dysfunction of vesicular storage
activity regulates lysosomal glucocerebrosidase in neurons in young-onset Parkinson’s patient-derived dopaminergic
derived from Parkinson’s disease patients. Nat Commun. neurons and organoids revealed by single cell electrochemical
2019;10(1):5570. cytometry. Chem Sci. 2022;13(21):6217-6223.
doi: 10.1038/s41467-019-13413-w doi: 10.1039/d2sc00809b
59. Sanyal A, DeAndrade MP, Novis HS, et al. Lysosome 70. Jarazo J, Barmpa K, Modamio J, et al. Parkinson’s disease

Volume 1 Issue 2 (2025) 11 doi: 10.36922/OR025040006